Neogen Corporation Profile Avatar - Palmy Investing

Neogen Corporation

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test…
Medical - Diagnostics & Research
US, Lansing [HQ]

Ratios

14 Sheets · Starting from 2023
Margins, Growth Rates In %
Ratio 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Profitability
Gross Margin
51.94 50.84 50.22 52.76 49.55 49.35 47.64 47.56 47.30 46.34 46.94 45.91 46.10 49.36
Profit Margin
12.47 13.23 12.23 13.10 11.38 11.84 11.38 12.11 15.70 14.53 14.22 13.00 9.16 -2.78
Operating Margin
19.13 20.75 18.33 19.61 17.54 18.76 17.55 17.96 17.45 12.19 11.75 11.34 6.62 4.56
EPS Growth
18.75 31.58 -4.00 16.67 3.57 17.24 5.88 19.44 41.86 -4.92 -1.72 - - -21.05 -126.67
Return on Assets (ROA)
9.72 10.40 8.95 9.40 8.15 8.55 8.09 8.29 10.22 8.65 7.46 6.62 4.87 -0.50
Return on Equity (ROE)
11.45 12.11 10.28 10.53 9.19 9.55 9.05 9.28 11.27 9.43 8.20 7.24 5.44 -0.73
Return on Invested Capital (ROIC)
11.26 12.31 10.21 10.36 9.23 9.81 9.18 9.08 10.78 6.53 5.56 5.10 3.15 0.96
Solvency
Equity Ratio
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
Debt/Assets
- - - - - - - - - - -0.51 - - - - - - - - 0.25 0.27 0.33 19.83
Debt/Equity
- - - - - - - - - - -0.57 - - - - - - - - 0.27 0.30 0.36 28.82
Debt/EBITDA
-86.27 -85.64 -203.46 -209.72 -176.30 -214.93 -191.18 -221.16 -300.33 -392.88 -507.41 -512.08 1,033.19 1,963.91
Debt/Capitalization
- - - - - - - - - - -0.57 - - - - - - - - 0.27 0.30 0.36 22.37
Interest Debt per Share USD
- - - - - - - - - - -0.02 - - - - - - -0.22 0.02 0.02 0.04 5.08
Debt Growth
- - - - - - - - - - - - - - - - - - - - - - 21.93 76,613.00 -8.79
Liquidity
Current Ratio
505.02 688.33 720.46 950.66 755.98 908.21 874.19 813.74 971.33 1,175.21 1,108.30 1,103.47 805.20 402.78
Quick Ratio
294.95 476.02 620.14 899.84 657.74 870.03 797.21 772.95 1,079.49 1,505.69 1,455.50 1,452.26 1,049.92 274.16
Cash Ratio
133.89 201.40 343.59 481.79 306.39 448.48 376.94 398.96 544.90 699.39 708.76 711.00 489.51 112.21
Operating Cash Flow Ratio
100 100 100 100 - - 100 100 100 100 100 100 100 - - - -
Turnover
Inventory Turnover
215.65 265.33 261.83 255.86 243.87 277.88 261.32 259.25 278.93 258.47 233.44 251.64 232.31 311.25
Receivables Turnover
512.19 603.07 516.23 535.74 476.69 478.10 474.89 527.29 508.63 501.55 493.82 510.18 528.88 536.66
Payables Turnover
939.67 996.84 851.50 1,064.20 931.67 1,047.32 1,064.63 1,167.36 1,021.69 1,165.96 865.07 1,060.26 820.90 543.23
Asset Turnover
77.96 78.61 73.15 71.75 71.65 72.18 71.12 68.43 65.09 59.53 52.46 50.91 53.09 18.06
Coverage
Interest Coverage
- - - - - - - - - - - - - - - - - - -224.42 - - 68,112.82 2,756.43 67.04
Asset Coverage
- - - - - - - - - - - - - - - - - - - - 64,700 60,200 - - 300
Cash Flow Coverage (CFGR)
- - - - - - - - - - -2,199.50 - - - - - - - - 4,365.94 3,253.97 2,107.74 4.54
EBITDA Coverage
- - - - - - - - - - - - - - - - - - -300 - - 95,000 4,600 - -
Dividend Coverage
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
Time Interest Earned (TIE)
100 100 100 100 100 100 100 100 100 100 100 100 100 100
Market Prospects
Dividend Yield
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
Earnings Yield
3.00 2.21 2.45 2.08 2.03 1.93 1.97 1.81 1.61 2.06 1.58 1.25 1.70 -0.69
Price/Earnings (P/E)
3,334.28 4,516.98 4,087.53 4,820.05 4,929.30 5,188.76 5,074.23 5,522.06 6,202.22 4,858.03 6,347.53 7,980.17 5,898.36 -14,444.81
Price/Book (P/B)
381.70 546.87 420.09 507.41 453.15 495.66 459.06 512.61 699.14 458.28 520.59 578.13 321.10 105.40
Price/Sales (P/S)
415.77 597.41 500.00 631.52 561.02 614.53 577.49 668.78 973.62 705.81 902.79 1,037.12 540.50 401.67
Price/Cash Flow (P/CF)
2,087.32 3,576.72 4,130.83 4,934.19 6,405.72 3,972.38 5,251.32 4,012.13 5,665.18 4,579.07 4,395.99 5,991.55 4,187.83 8,051.89
End of NEOG's Analysis
CIK: 711377 CUSIP: 640491106 ISIN: US6404911066 LEI: - UEI: -
Secondary Listings
NEOG has no secondary listings inside our databases.